Industry symposia

 Thursday, 29 October 2026       13:15 - 14:15

Symposium objectives

• Describe the autoimmune pathophysiology of type 1 diabetes (T1D) and how the early stages of disease progression (Stages 1 and 2) can be quantified prior to clinical onset (Stage 3)
• Discuss the clinical importance of detecting early-stage T1D by islet autoantibody (IAb) screening and how to identify people at increased risk of autoimmune T1D
• Explore the essential role pediatricians have in advancing the early detection of T1D worldwide

agenda as of 25 September 2026, agenda subject to change

Back to symposium overview

 Thursday, 29 October 2026       13:15 - 14:15

Session description

Health-Related Quality of Life (HRQoL) is a key outcome in paediatric health care and decision-making. However, its measurement and implementation require consideration of unique developmental challenges across infancy, childhood and adolescence. Selecting and implementing these measures requires careful consideration in all contexts. This symposium provides a comprehensive exploration of neonatal and paediatric HRQoL measurement, beginning with an overview of age-appropriate assessment and the EuroQol model for measurement and valuation by Janine Verstraete. Building on these foundations, David Mott examines the strategic application of EuroQol HRQoL outcome measures, the EQ-5D-Y and EQ-TIPS, in clinical trials and research studies illustrated through examples from neonatal care with extremely preterm babies and Juvenile Idiopathic Arthritis. Finally, Ling Jie Cheng highlights the translation of these tools into routine clinical practice, demonstrating their vital role in enhancing holistic clinical decision-making, patient communication, and timely referral pathways.

agenda as of 4 September 2026, agenda subject to change

Back to symposium overview

 Thursday, 29 October 2026       17:45 - 18:45

Overview

Infant RSV prevention has moved rapidly from evidence generation to programme implementation across Europe. Countries are now using different policy models, including maternal RSV vaccination, direct infant immunisation with long-acting monoclonal antibodies, and hybrid approaches that make both routes available. The central policy and implementation question is how programmes can achieve high, timely, equitable and measurable protection before or during an infant’s first RSV season.

This symposium will present findings from a CLCI policy report: Infant RSV Immunisation in Europe | Policy choices, coverage gaps and opportunities to improve equitable protection, which compares infant RSV protection across selected European markets, including the UK, Ireland, Germany, France, Spain, Denmark, Poland and Austria. The discussion will focus on programme models, coverage and equity gaps, implementation experience and examples of best practice, to translate early lessons into practical policy recommendations.

Objectives

• Present the main findings and policy recommendations from the CLCI report on infant RSV immunisation in Europe.
• Compare national approaches to infant RSV protection, including maternal vaccination, infant long-acting monoclonal antibody programmes and hybrid models.
• Highlight early implementation lessons from countries with established or emerging infant RSV prevention programmes.
• Discuss coverage, catch-up and equity challenges, including how to identify and reach infants who may be missed.
• Identify practical actions for policymakers, public health authorities and clinical leaders to support more equitable infant RSV protection across Europe.

Intended outputs from the session

• Greater awareness of the different infant RSV prevention models now being implemented across Europe.
• Clearer understanding of coverage, equity and implementation challenges.
• Practical examples of good practice from early programme experience.
• Strengthened engagement with scientific leaders, policymakers and patient/family voices.
• A focused call to action on timely, equitable and measurable infant RSV protection.

status as of 17 September 2026

Back to symposium overview

 Friday, 30 October 2026       08:00 - 08:30

Session description

This symposium aims to raise awareness of the impact of invasive meningococcal disease (IMD) in infants. The symposium will explore the evolving landscape of IMD prevention across Europe, focusing on the importance of vaccination strategies across ages with focus on the youngest ones, to help prevent the unthinkable.

Disclaimer: the presented data for infants may be not aligned with French vaccination recommendations

agenda as of 27 July 2026, agenda subject to change

Back to symposium overview

 Friday, 30 October 2026       08:00 - 08:30

Session description

This symposium explores how infusion-system architecture influences the dose actually delivered to patients receiving multiple intravenous medications. It connects the fundamental physics of common volume and low-flow drug delivery with the design rationale of a dedicated multi-infusion architecture and published neonatal clinical experience.

Particular attention will be given to how infusion-system design and clinical implementation may contribute to more predictable drug delivery, fewer manipulations close to the central line, and the prevention of central-line-associated bloodstream infections.

Programme

Back to symposium overview

 Friday, 30 October 2026       12:30 - 13:30

Session agenda

AIP, all-infant protection; LRTD, lower respiratory tract disease; RSV, respiratory syncytial virus.

agenda as of 22 September 2026, agenda subject to change

Back to symposium overview

 Friday, 30 October 2026       12:30 - 13:30

agenda as of 7 September 2026, agenda subject to change

Back to symposium overview

 Friday, 30 October 2026       12:30 - 13:30

agenda as of 4 September 2026, agenda subject to change

Back to symposium overview